Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies
Frontiers in Drug Delivery · 2022
DOI: 10.3389/fddev.2022.1043756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Drug Delivery, 2022. Verfasst von Timothy S Dutill und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lyophilization Technology, Inc, Warminster, PA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Promising clinical efficacy results have generated considerable enthusiasm for the potential impact of adjuvant-containing subunit tuberculosis vaccines. The development of a thermostable tuberculosis vaccine formulation could have significant benefits on both the cost and feasibility of global vaccine distribution. The tuberculosis vaccine candidate ID93 + GLA-SE has reached Phase 2 clinical testing, demonstrating safety and immunogenicity as a two-vial point-of-care mixture. Earlier publications have detailed efforts to develop a lead candidate single-vial lyophilized thermostable ID93 + GLA-SE vaccine formulation. The present report describes the lyophilization process development and scale-up of the lead candidate thermostable ID93 + GLA-SE composition. The manufacture of three full-scale engineering batches was followed by one batch made and released under current Good Manufacturing Practices (cGMP). Up to 4.5 years of stability data were collected. The cGMP lyophilized ID93 + GLA-SE passed all manufacturing release test criteria and maintained stability for at least 3 months when stored at 37°C and up to 24 months when stored at 5°C. This work represents the first advancement of a thermostable adjuvant-containing subunit tuberculosis vaccine to clinical testing readiness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lyophilization Technology, Inc, Warminster, PA, USA.
- Access to Advanced Health Institute (AAHI; formerly Infectious Disease Research Institute), Seattle, WA, USA.
- Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria.
- Department of Global Health, University of Washington, Seattle, WA, USA.
Förderung
- NIAID NIH HHS
Zitieren
APA
Dutill, T. S., Archer, M. C., McCollum, J., Press, C., McNeill, L., Hawkins, L., Phan, T., Laursen, E., Cabullos, R., Bouchard, L., Castro, R. J., Lin, M. W., Roco, J., Blois, C., Adeagbo, B., Guderian, J. A., Gerhardt, A., Beckmann, A. M., Trappler, E. H., …, & Fox, C. B. (2022). Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies. Frontiers in Drug Delivery. https://doi.org/10.3389/fddev.2022.1043756
Vancouver
Dutill TS, Archer MC, McCollum J, Press C, McNeill L, Hawkins L, et al. Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies. Frontiers in Drug Delivery. 2022. doi:10.3389/fddev.2022.1043756
BibTeX
@article{Dutill2022,
author = {Dutill, Timothy S and Archer, Michelle C and McCollum, Joseph and Press, Chris and McNeill, Lisa and Hawkins, Linda and Phan, Tony and Laursen, Erik and Cabullos, Richard and Bouchard, Lisa and Castro, Regie J and Lin, Mong-Wu and Roco, Jeralyn and Blois, Cecile and Adeagbo, Babatunde and Guderian, Jeffrey A and Gerhardt, Alana and Beckmann, Anna Marie and Trappler, Edward H and Kramer, Ryan M and Fox, Christopher B},
title = {Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies},
journal = {Frontiers in Drug Delivery},
year = {2022},
doi = {10.3389/fddev.2022.1043756}
}
EUVIMED